Navigation Links
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Date:5/18/2009

Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced new data today from multiple studies of torezolid (TR-701), a novel antibiotic that is a potent inhibitor of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Data presented at ECCMID demonstrate that MRSA and MSSA strains exposed in vitro to torezolid developed spontaneous resistance at a 16-fold lower frequency than strains exposed to linezolid (Zyvox(R)), the only drug of the oxazolidinone class currently marketed. Poster presentations on TR-701 also highlighted data characterizing torezolid's pharmacodynamics, high intracellular concentrations and resulting bactericidal activity. Human Phase 1 clinical studies showed that oral torezolid, administered at doses from 200 to 400 mg once a day over 21 days, is safe and well tolerated, and that its oral bioavailability is not affected by the administration of food.

"These new study results presented by Trius and external investigators validate the compound's increased potency and ability to reach bacterial pathogens in high concentration inside the tissues while also supporting a favorable safety and tolerability profile," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "As a result, there is significant interest from the medical community in torezolid, a second generation oxazolidinone, especially for the treatment of infections caused by S. aureus, including MRSA."

Posters/abstracts are available on the Trius Web site at www.triusrx.com/posters.

"As bacterial pathogens like MRSA continue developing resistance to current treatments, clinicians are more acutely aware of the need for an alternative that is less susceptible to resistance development along with a once a day dosing regimen which promotes higher compliance," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We will release top-line Phase 2 data in the coming weeks and plan to initiate Phase 3 testing in early 2010. Our goal is to provide physicians and patients with a best-in-class therapy as soon as possible."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Atrius Health Selects rL Solutions for Improved Patient Safety and Quality of Care
2. Trius Raises $30 Million in Series B Financing
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
5. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
6. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
7. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
8. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
9. American Association for Homecare Applauds Senate Subcommittee Efforts to Prevent Waste and Fraud in Medicare; Association Presents 13-Point Legislative Plan to Stop Waste and Fraud
10. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of Cosmetic Surgery, ... pleased to announce a new treatment option called Vivace Microneedling. This treatment option ... and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
(Date:5/23/2017)... Segundo, CA (PRWEB) , ... May 23, 2017 ... ... braces can now receive treatment using the SPEED System™ Orthodontics, with or without ... respected orthodontist in El Segundo, CA, who is skilled in providing ...
(Date:5/22/2017)... ... , ... Patients who avoid necessary dental and endodontic treatments because of ... from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three different sedation ... methods may be recommended based on the severity of the anxiety experienced by each ...
(Date:5/22/2017)... PAUL, Minn. (PRWEB) , ... May 22, 2017 , ... ... young man’s experience learning to live with Bipolar 1. Donald Rodriguez takes readers on ... mountain in Alaska in the dead of winter and to a dark place where ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
Breaking Medicine Technology: